Prev Close | 22.12 |
Open | 21.92 |
Day Low/High | 21.53 / 22.53 |
52 Wk Low/High | 20.20 / 62.16 |
Volume | 390.49K |
Prev Close | 22.12 |
Open | 21.92 |
Day Low/High | 21.53 / 22.53 |
52 Wk Low/High | 20.20 / 62.16 |
Volume | 390.49K |
Exchange | NASDAQ |
Shares Outstanding | 54.79B |
Market Cap | 1.17B |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
Here's a rundown of four technical setups that are showing solid trading potential.
Celgene's days of stellar growth will continue to stretch far into the future.
The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.
Risks far outweigh the possible rewards of buying into late bullishness.
At the very least, move those stop loss levels in very close on long positions.
Follow these maxims and you should do well in this volatile sector.
TheStreet's Jim Cramer answers viewers' questions on Allergan, Pfizer, Disney, MasterCard, Chipotle, Under Armour and more.
Picking up some high yielders might be worthwhile.
Own them, or take something off the table?
And they're both named Bob.
But tomorrow we hear from the banks.
The chasing in certain areas was intense.
I would continue to take any buy triggers in this one.
Throughout this historic run, four groups have consistently led the market.
Also on Agios Pharmaceuticals
But stay disciplined, honor your stops and protect gains.
The end-of-the-year phenomenon is working.
In this era of turmoil, investors can take comfort in this sector.
As 2014 winds down, you could almost throw darts at these standout groups -- but here are my own picks.
This market provides a slew of reasons to buy right now.
Bet with common sense not against it.